Congenital CMV: Difference between revisions

From IDWiki
m (β†’β€: semantic links)
Line 1: Line 1:
== Epidemiology ==
==Epidemiology==


*Maternal seroconversion in about 2% of pregnancies
* Risk of transmission to fetus
**Higher in childcare workers
** '''Primary infection''': 30% risk of congenital CMV; higher risk later in pregnancy, but worse outcomes earlier
*Risk of transmission to fetus
** Non-primary
**'''Primary infection''': 30% risk of congenital CMV; higher risk later in pregnancy, but worse outcomes earlier
*** '''Reinfection''': 5% risk
**Non-primary
*** '''Reactivation''': 1% risk
***'''Reinfection''': 5% risk
***'''Reactivation''': 1% risk


== Clinical Presentation ==
==Clinical Presentation==
* Mother may have had asymptomatic infection
* At birth
** [[Causes::Microcephaly]]
** [[Causes::Periventricular calcifications]]
** [[Causes::Chorioretinitis]]
** [[Causes::Sensorineural hearing loss]]
** [[Causes::Optic nerve atrophy]]
** [[Causes::Hepatosplenomegaly]]
** [[Causes::Cytopenias]]
* Later
** [[Causes::Cognitive deficits]] (7%)
** [[Causes::Sensorineural hearing loss]] (20%)


*Mother may have had asymptomatic infection
== Diagnosis ==
*At birth
**[[Causes::Microcephaly]]
**[[Causes::Periventricular calcifications]]
**[[Causes::Chorioretinitis]]
**[[Causes::Sensorineural hearing loss]]
**[[Causes::Optic nerve atrophy]]
**[[Causes::Hepatosplenomegaly]]
**[[Causes::Cytopenias]]
*Later
**[[Causes::Cognitive deficits]] (7%)
**[[Causes::Sensorineural hearing loss]] (20%)


==Diagnosis==
* In mom, IgM antibodies
* In baby, urine PCR within 2 weeks of birth


*In mom, IgM antibodies
== Management ==
*In baby, urine PCR within 2 weeks of birth


==Management==
* Treatment is indicated for symptomatic babies
** Brain
** Hearing
** Eye
* IV [[Is treated by::ganciclovir]] or PO [[Is treated by::valganciclovir]], for 6 months
* Monitor CBC while on therapy


*Treatment is indicated for symptomatic babies
**Brain
**Hearing
**Eye
*IV [[Is treated by::ganciclovir]] or PO [[Is treated by::valganciclovir]], for 6 months
*Monitor CBC while on therapy


[[Category:Pediatrics]]
[[Category:Pediatrics]]

Revision as of 00:33, 14 July 2020

Epidemiology

  • Maternal seroconversion in about 2% of pregnancies
    • Higher in childcare workers
  • Risk of transmission to fetus
    • Primary infection: 30% risk of congenital CMV; higher risk later in pregnancy, but worse outcomes earlier
    • Non-primary
      • Reinfection: 5% risk
      • Reactivation: 1% risk

Clinical Presentation

Diagnosis

  • In mom, IgM antibodies
  • In baby, urine PCR within 2 weeks of birth

Management

  • Treatment is indicated for symptomatic babies
    • Brain
    • Hearing
    • Eye
  • IV ganciclovir or PO valganciclovir, for 6 months
  • Monitor CBC while on therapy

References

  1. ^  Gisela Enders, Anja Daiminger, Ursula BΓ€der, Simone Exler, Martin Enders. Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. Journal of Clinical Virology. 2011;52(3):244-246. doi:10.1016/j.jcv.2011.07.005.